Live Breaking News & Updates on Dermatomyositis pro
Stay updated with breaking news from Dermatomyositis pro. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- DelveInsight's Dermatomyositis Market Insights report includes a comprehensive understanding of current treatment practices, dermatomyositis...
The dynamics of the dermatomyositis market are anticipated to change in the coming years owing to the improvement in the rise in a number of healthcare spending across the world and rising cases
ProDERM Study Results of octagam® 10% Treatment in Patients With Dermatomyositis Published in the New England Journal of Medicine q8dailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from q8dailynews.com Daily Mail and Mail on Sunday newspapers.
email article Treatment with intravenous immunoglobulins (IVIG) for dermatomyositis was effective in a pivotal phase III randomized trial, a researcher reported. At week 16, 78.72% of patients receiving IVIG were considered responders versus 43.75% among those given placebo, which represented a difference of 34.97% (95% CI 16.70-53.24, P=0.0008). "This was a highly significant difference," said Rohit Aggarwal, MD, co-director of the Myositis Center at the University of Pittsburgh, during a plenary abstract session at the European League Against Rheumatism (EULAR) virtual congress. "Dermatomyositis is a rare, chronic autoimmune disease characterized by progressive proximal muscle weakness and a characteristic skin rash," he explained. Current therapeutic options include corticosteroids, other immunosuppressants, and IVIG. However, none of these therapies have been evaluated in phase III studies.